KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biomarin Pharmaceutical (BMRN) Other Non-Current Assets: 2009-2024

Historic Other Non-Current Assets for Biomarin Pharmaceutical (BMRN) over the last 16 years, with Dec 2024 value amounting to $251.4 million.

  • Biomarin Pharmaceutical's Other Non-Current Assets rose 35.86% to $270.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $270.8 million, marking a year-over-year increase of 35.86%. This contributed to the annual value of $251.4 million for FY2024, which is 46.55% up from last year.
  • As of FY2024, Biomarin Pharmaceutical's Other Non-Current Assets stood at $251.4 million, which was up 46.55% from $171.5 million recorded in FY2023.
  • Biomarin Pharmaceutical's 5-year Other Non-Current Assets high stood at $251.4 million for FY2024, and its period low was $142.2 million during FY2020.
  • For the 3-year period, Biomarin Pharmaceutical's Other Non-Current Assets averaged around $199.7 million, with its median value being $176.2 million (2022).
  • Per our database at Business Quant, Biomarin Pharmaceutical's Other Non-Current Assets fell by 2.67% in 2023 and then soared by 46.55% in 2024.
  • Over the past 5 years, Biomarin Pharmaceutical's Other Non-Current Assets (Yearly) stood at $142.2 million in 2020, then rose by 6.95% to $152.1 million in 2021, then increased by 15.85% to $176.2 million in 2022, then fell by 2.67% to $171.5 million in 2023, then surged by 46.55% to $251.4 million in 2024.